Bayer (BAYRY) announced positive results from the expansion part of the ongoing early to mid-stage study on pipeline candidate BAY 2927088. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR) with high selectivity for mutant versus wild-type EGFR. The phase I/II SOHO-01 study evaluates the safety and pre ...

Core Viewpoint - Bayer's Q2 2024 results were mixed, with strong performance in Pharmaceuticals but challenges in Crop Science, leading to a downgrade in stock valuation from Deep Value to Speculative Value [1][10] Financial Performance - Bayer reported total revenues of €11.1 billion for Q2 2024, a 3% increase from the consensus estimate of €10.8 billion [2] - EBITDA before special items was €2.1 billion, a 2% increase over the consensus estimate of €2.08 billion, while core EPS rose 13% to €0.94, outperforming expectations [2] - Pharmaceuticals division sales increased by 4% to €4.6 billion, exceeding consensus by €191 million, with EBITDA before special items rising 12% YoY to €1.32 billion [2] - Crop Science division faced challenges, with sales of €4.98 billion, just 1% above consensus, but a 25% miss on EBITDA at €524 million [2] - Consumer Health segment reported a 1% increase in sales to €1.46 billion, but a 6% decline in EBITDA to €314 million [2] Cost Management and Restructuring - Bayer is implementing a cost-cutting strategy targeting over €2 billion in structural savings by 2026, with a workforce reduction of approximately 1,500 positions [3] - Headcount has been reduced by nearly 5% YoY, focusing on eliminating bureaucratic layers and unproductive segments [3] Guidance and Outlook - Bayer reiterated its FY24 guidance, expecting group sales around €47.6 billion and an EBITDA margin between 22.5% and 22.6% [4] - The Pharma division's growth guidance was upgraded, while Crop Science is expected to perform at the lower end of sales and EBITDA guidance [4] Litigation Developments - Bayer settled 114,000 out of 172,000 glyphosate-related claims as of Q2, with a significant legal win in the "Schaffner vs. Monsanto" case [5] - The U.S. Third Circuit Court of Appeals ruled in favor of Bayer, which may lead to a Supreme Court review, potentially impacting ongoing glyphosate litigation [5] Long-term Growth Potential - Bayer plans to launch ten blockbuster agricultural products over the next decade, with total revenue potential exceeding €32 billion [6] - The company is focusing on innovative R&D, including new herbicides and digital tools to enhance farming practices [6] Valuation Update - Following Q2 2024 results, Bayer's fair implied share price is updated to €44, reflecting adjusted EPS expectations through 2026 [7][10]

Bayer (BAYRY) announced encouraging detailed results from the late-stage FINEARTS-HF study on finerenone. Finerenone is marketed as Kerendia or Firialta in some countries. The drug is approved for the treatment of adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in more than 90 countries worldwide, including China, Europe, Japan and the United States. It is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block the harmful eff ...

Bayer (BAYRY) announces the initiation of the phase II, ALPINE-1 study, on pipeline candidate BAY3283142 following the successful first-in-human trials. BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, is being evaluated for patients with chronic kidney disease (CKD). APLINE-1 is a randomized, double-blind, placebo-controlled, multicenter study that will assess the efficacy and safety of BAY3283142 in CKD patients. CKD is a progressive condition affecting more than 10% of the global ...

Key Takeaways A U.S. appeals court ruled in favor of Bayer-owned Monsanto in a lawsuit alleging the company failed to warn customers about the cancer risk of its Roundup weed killer. The court said state labeling requirements cannot usurp federal ones, and the Environmental Protection Agency (EPA) did not require a cancer warning on Roundup. The decision conflicts with those from other courts, and the company argued that the U.S. Supreme Court should settle the issue. In a big victory for Bayer-owned Monsan ...

CHICAGO, ILLINOIS - MAY 14: Roundup weed killing products are offered for sale at a home improvement store on May 14, 2019 in Chicago, Illinois. A jury yesterday ordered Monsanto, the maker of Roundup, to pay a California couple more than $2 billion in damages after finding that the weed killer had caused their cancer. This is the third jury to find Roundup had caused cancer since Bayer purchased Monsanto about a year ago. Bayer's stock price has fallen more than 40 percent since the takeover. (Photo by Sco ...

JHVEPhoto One of my investments that was a huge disappointment in the recent past was the German life science company Bayer Aktiengesellschaft (OTCPK:BAYZF). Of course, one could argue that Bayer investors are now used to disappointments as the stock is now declining for almost 10 years and every time when investors assumed it couldn't get any worse, terrible new news came up and the stock was continuing to decline. My last article about Bayer was published about three months ago following first quarter res ...

Fotofantastika Dear readers/followers, I've been very careful about pharma company Bayer (OTCPK:BAYRY) since my last article. You can find that particular article here. When I last wrote about Bayer, the company had just cut the dividend to the bone (less than 1% at the time of publishing of that piece). It's fair to say that the fortunes for Bayer have turned around over the past 3 years and that there's according to the valuation not much reason for near-term optimism to be had here. The cases to be made ...

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Jost Reinhard - IR William N. Anderson - Chairman & CEO Wolfgang U. Nickl - CFO Julio Triana - President, Consumer Health Division Stefan Oelrich - President, Pharmaceuticals Division Rodrigo Santos - President, Crop Science Division Conference Call Participants Vincent Andrews - Morgan Stanley Peter Verdult - Citibank Sachin Jain - Bank of America Christian Faitz - Kepler Cheuvreux Emily F ...

Bayer AG (BAYRY) reported second-quarter 2024 core earnings of 25 cents per American Depositary Receipt (ADR), on par with the Zacks Consensus Estimate. The company reported earnings of 33 cents per ADR in the year-ago quarter. Core earnings of €0.94 per share deteriorated 23% year over year due to a decline in earnings at the Crop Science Division. Total sales in the reported quarter were $12 billion (€11.14 billion), up 0.9% on a reported basis as volume growth of 1.6% and positive pricing impact of 1.5% ...